Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Get Free Report) has received a consensus rating of “Moderate Buy” from the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $57.2857.
Several equities analysts recently issued reports on the company. Morgan Stanley set a $43.00 target price on Immunocore in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of Immunocore in a research note on Monday, April 20th. Zacks Research raised shares of Immunocore from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 5th. Mizuho lifted their price objective on shares of Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a report on Monday, July 13th.
Read Our Latest Analysis on IMCR
Key Headlines Impacting Immunocore
- Positive Sentiment: Kimmtrak revenue increased 18.3% year over year, supported by higher sales in the United States and international markets. The drug remains Immunocore’s sole commercial product and the primary driver of revenue growth. Immunocore’s Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
- Positive Sentiment: Zacks Research upgraded Immunocore from “hold” to “strong-buy.” Separately, the average Wall Street price target implies substantial potential upside, although price-target accuracy is uncertain. Immunocore analyst upgrade Wall Street Analysts See a 77.91% Upside in Immunocore
- Neutral Sentiment: Management’s second-quarter earnings presentation and conference call highlighted Kimmtrak growth and the company’s development pipeline. Investors will likely focus on the pace of commercial expansion and progress toward additional pipeline opportunities. Immunocore 2026 Q2 Results Presentation
- Negative Sentiment: Immunocore reported a second-quarter loss of $0.02 per share, wider than the $0.01 expected loss. Revenue was approximately $115.9 million; while sales grew year over year, this figure was below the cited analyst consensus of $148.4 million. The company also remained unprofitable, increasing concern about the timing of sustainable earnings. Immunocore Q2 Earnings Report
Immunocore Price Performance
Immunocore stock opened at $34.00 on Monday. The company has a market capitalization of $1.73 billion, a PE ratio of -91.89 and a beta of 0.74. The company has a debt-to-equity ratio of 0.94, a quick ratio of 4.44 and a current ratio of 4.47. Immunocore has a fifty-two week low of $27.56 and a fifty-two week high of $40.71. The firm has a 50 day moving average price of $31.64 and a 200 day moving average price of $31.33.
Immunocore (NASDAQ:IMCR – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%.The firm had revenue of $115.93 million for the quarter, compared to analysts’ expectations of $148.58 million. Research analysts expect that Immunocore will post -0.02 earnings per share for the current year.
Institutional Trading of Immunocore
A number of large investors have recently made changes to their positions in the company. Harbour Investments Inc. raised its position in shares of Immunocore by 60.2% during the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after acquiring an additional 388 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Immunocore by 37.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after purchasing an additional 572 shares in the last quarter. R Squared Ltd increased its stake in Immunocore by 7.4% in the fourth quarter. R Squared Ltd now owns 8,849 shares of the company’s stock valued at $307,000 after purchasing an additional 606 shares during the last quarter. Leonteq Securities AG acquired a new stake in Immunocore during the fourth quarter worth approximately $30,000. Finally, Orion Porfolio Solutions LLC raised its holdings in Immunocore by 4.5% during the second quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company’s stock worth $752,000 after purchasing an additional 1,031 shares in the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.
About Immunocore
Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.
The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.
Featured Stories
- Five stocks we like better than Immunocore
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
